These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10469053)

  • 1. Vaccines for preventing malaria (SPf66).
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD005966. PubMed ID: 16625647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic skin-permeable proteins enabling needleless immunization.
    Huang Y; Park YS; Moon C; David AE; Chung HS; Yang VC
    Angew Chem Int Ed Engl; 2010 Apr; 49(15):2724-7. PubMed ID: 20232417
    [No Abstract]   [Full Text] [Related]  

  • 3. Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.
    Asadi K; Gholami A
    Int J Biol Macromol; 2021 Jul; 182():648-658. PubMed ID: 33862071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.
    Soema PC; Rosendahl Huber SK; Willems GJ; Jiskoot W; Kersten GF; Amorij JP
    Pharm Res; 2015 Apr; 32(4):1505-15. PubMed ID: 25344321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virosome presents multimodel cancer therapy without viral replication.
    Saga K; Kaneda Y
    Biomed Res Int; 2013; 2013():764706. PubMed ID: 24369016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New age adjuvants and delivery systems for subunit vaccines.
    Kurella S; Manocha M; Sabhnani L; Thomas B; Rao DN
    Indian J Clin Biochem; 2000 Aug; 15(Suppl 1):83-100. PubMed ID: 23105272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.
    Cech PG; Aebi T; Abdallah MS; Mpina M; Machunda EB; Westerfeld N; Stoffel SA; Zurbriggen R; Pluschke G; Tanner M; Daubenberger C; Genton B; Abdulla S
    PLoS One; 2011; 6(7):e22273. PubMed ID: 21799810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.
    Tamborrini M; Mueller MS; Stoffel SA; Westerfeld N; Vogel D; Boato F; Zurbriggen R; Robinson JA; Pluschke G
    Malar J; 2009 Dec; 8():314. PubMed ID: 20042100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.
    Okitsu SL; Silvie O; Westerfeld N; Curcic M; Kammer AR; Mueller MS; Sauerwein RW; Robinson JA; Genton B; Mazier D; Zurbriggen R; Pluschke G
    PLoS One; 2007 Dec; 2(12):e1278. PubMed ID: 18060072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
    Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
    PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
    Westerfeld N; Pluschke G; Zurbriggen R
    Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virosomes as new carrier system for cancer vaccines.
    Schwaninger R; Waelti E; Zajac P; Wetterwald A; Mueller D; Gimmi CD
    Cancer Immunol Immunother; 2004 Nov; 53(11):1005-17. PubMed ID: 15185010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.
    Mueller MS; Renard A; Boato F; Vogel D; Naegeli M; Zurbriggen R; Robinson JA; Pluschke G
    Infect Immun; 2003 Aug; 71(8):4749-58. PubMed ID: 12874357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a conserved, stage-specific gene product of Plasmodium falciparum recognized by parasite growth inhibitory antibodies.
    Daubenberger CA; Diaz D; Curcic M; Mueller MS; Spielmann T; Certa U; Lipp J; Pluschke G
    Infect Immun; 2003 Apr; 71(4):2173-81. PubMed ID: 12654839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro.
    Moreno R; Pöltl-Frank F; Stüber D; Matile H; Mutz M; Weiss NA; Pluschke G
    Infect Immun; 2001 Apr; 69(4):2558-68. PubMed ID: 11254620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
    Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
    Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune responses during a malaria vaccine trial in Tanzanian infants.
    Galindo CM; Acosta CJ; Schellenberg D; Aponte JJ; Roca A; Oettli A; Urassa H; Armstrong Schellenberg J; Kahigwa E; Ascaso C; Mshinda H; Lwilla F; Vidal J; Menendez C; Tanner M; Alonso PL
    Parasite Immunol; 2000 Sep; 22(9):437-43. PubMed ID: 10972850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
    Kashala O; Amador R; Valero MV; Moreno A; Barbosa A; Nickel B; Daubenberger CA; Guzman F; Pluschke G; Patarroyo ME
    Vaccine; 2002 May; 20(17-18):2263-77. PubMed ID: 12009282
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.